Development of a liquid chromatography assay for the determination of opicapone and BIA 9–1079 in rat matrices

Abstract

Opicapone is a novel potent, reversible and purely peripheral third generation catechol-O-methyltransferase inhibitor, currently under clinical trials as an adjunct to levodopa therapy for Parkinson's disease. To support additional nonclinical pharmacokinetic studies, a novel high-performance liquid chromatographic method coupled to a diode array detector (HPLC-DAD) to quantify opicapone and its active metabolite (BIA 9-1079) in rat plasma and tissues (liver and kidney) is herein reported. The analytes were extracted from rat samples through a deproteinization followed by liquid-liquid extraction. Chromatographic separation was achieved in less than 10 min on a reversed-phase C18 column, applying a gradient elution program with 0.05 M monosodium phosphate solution (pH 2.45 ± 0.05) and acetonitrile. Calibration curves were linear (r(2) ≥ 0.994) within the ranges of 0.04-6.0 µg/mL for both analytes in plasma, 0.04-4.0 µg/mL for opicapone in liver and kidney homogenates, and 0.07-4.0 µg/mL and 0.06-4.0 µg/mL for BIA 9-1079 in liver and kidney homogenates, respectively. The overall intra- and inter-day accuracy ranged from -12.68% to 7.70% and the imprecision values did not exceed 11.95%. This new HPLC-DAD assay was also successfully applied to quantify opicapone and BIA 9-1079 in a preliminary pharmacokinetic study.